[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Synthomer Plc LSE:SYNT London Ordinary Share GB0009887422 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.40 -0.94% 465.80 465.40 466.00 478.80 462.60 478.80 512,732 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 1,644.2 20.3 0.7 665.4 1,979

Synthomer Share Discussion Threads

Showing 501 to 521 of 525 messages
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
DateSubjectAuthorDiscuss
07/9/2021
14:43
Why is it not a surprise?
scooper72
07/9/2021
14:16
Strike HTTPS://actu.fr/normandie/sandouville_76660/nouveau-debrayage-de-plusieurs-dizaines-de-salaries-de-synthomer-pres-du-havre_44594676.html
philanderer
23/8/2021
19:59
Hound partners have increased their short. Not surprising really
login
23/8/2021
11:15
UBS RAISES SYNTHOMER PRICE TARGET TO 550 (530) PENCE - 'NEUTRAL'
philanderer
09/8/2021
20:17
Your wife has a big future unless taken out by a predator?
rbewes
09/8/2021
19:11
p so is the wife I'm pleased to say. .
james dean
09/8/2021
18:14
Brilliant results and positive forecast. Also note the deleveraging which gives scope for investment/acquisitions. I think this is a company which has a big future unless taken out by a predator.
cardinal3
06/8/2021
21:00
Agree maurice, holding on to all mine.
philanderer
06/8/2021
19:35
I’d be bothered if that was all they made, but it isn’t. PE(F) of 10 seems low and a not terrible divi while I await the rerate. I think Berenberg have got this wrong. Time will tell obviously.
mauricemonkey
06/8/2021
18:15
(Sharecast News) - London's FTSE 250 was down 0.2% at 23,468.78 in afternoon trade on Friday. Synthomer was knocked lower by a downgrade to 'hold' from 'buy' at Berenberg. The bank said that while welcome, Synthomer's pre-released first-half results probably mark the end of the organic upgrade cycle. "For all management's work in upgrading the portfolio and reducing leverage, the stock appears to be entering a precarious phase for industrial names: increasing amounts of capex directed towards a level at which there is declining return on capital employed (nitrile latex). "Given two-year valuation is no longer low enough to make a compelling case for shares, we downgrade to hold with a new price target of 550p."
philanderer
06/8/2021
11:13
login, who has upgraded ? thanks
philanderer
06/8/2021
10:36
Just upgraded our target price to 727
login
06/8/2021
10:21
The 342k sell has been matched with a 350k buy.
farnesbarnes
06/8/2021
10:07
Some serious dumping going on ... 1 million + printed already.
philanderer
06/8/2021
09:49
Downgrade it is then.. BERENBERG CUTS SYNTHOMER TO 'HOLD' (BUY) - PRICE TARGET 550 (560) PENCE
philanderer
06/8/2021
00:26
Synthomer storms ahead Synthomer proves, if proof were needed, that even nitrile latex companies can have their day. HTTPS://www.investorschronicle.co.uk/news/2021/08/05/synthomer-storms-ahead/
philanderer
05/8/2021
21:54
I’ve had three COVID tests in the last eeek to travel. Every time a new pair of plastic disposable gloves. Use will continue for some time yet.
deanowls
05/8/2021
19:15
Canaccord put out a 'buy', tp 750p , on monday this week. ---------------- Canaccord ups price target on Synthomer Analysts at Canaccord Genuity raised their target price on chemicals outfit Synthomer from 700.0p to 750.0p on Monday, citing a fourth upgrade to full-year guidance. Synthomer announced a further update to its guidance for 2021 underlying earnings in July, EBITDA, now to "above £500.0m" from previous estimates of over £450.0m. The Canadian bank pointed out that the source of the further upgrade appeared to be broad-based. "Overall, we now expect net EPS to be up more than 150% this year on unit margins (€/ton) roughly doubling, with the overwhelming majority of that improvement coming from the nitrile business," said Canaccord. "Whilst normalisation is likely to come in the medium term, we continue to see super-normal profits in nitrile through 2022E, due both to the direct and ongoing impacts of the pandemic on PPE demand, but also the indirect increase in healthcare workers' (and others') demand for greater protection." As a result, Canaccord, which also stood by its 'buy' rating on the stock, upgraded 2022/23 EPS estimates by roughly 8% but also highlighted "increased optionality" at Synthomer, whether from the rapid debt reduction or opportunity for further expansion. [...]
philanderer
05/8/2021
14:45
bought more on the dips; very cheap at this price.
deadly
05/8/2021
12:03
...or maybe not ;-)
philanderer
05/8/2021
09:16
Looking good :-)
philanderer
Chat Pages: 21  20  19  18  17  16  15  14  13  12  11  10  Older
ADVFN Advertorial
Your Recent History
LSE
SYNT
Synthomer
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211022 00:21:19